Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Revive Therapeutics (RVVTF) AI Stock Analysis

58 Followers
RVVTF

Revive Therapeutics

(Other OTC:RVVTF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Low Debt BurdenVery low debt, including zero total debt in 2026, reduces near-term refinancing pressure and interest obligations. This gives Revive some financial flexibility while its drug candidates remain in development, although the benefit is constrained by negative equity and limited assets.
Negative Factors
No Commercial RevenueThe absence of revenue leaves Revive without a commercial funding base for its drug-development programs. Persistent dependence on future clinical progress and external capital makes operating performance highly sensitive to financing availability and delays in converting candidates into products.

Revive Therapeutics (RVVTF) vs. SPDR S&P 500 ETF (SPY)

-100%0%100%200%300%400%500%RVVTF+20.00%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$6.67M
Dividend Yield
―
Average Volume (3M)
188.12K
Price to Earnings (P/E)
-12.5
Beta (1Y)
-1.78
Revenue Growth
―
EPS Growth
91.01%
Country
US
Employees
2
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Revive Therapeutics Business Overview & Revenue Model

Company Description

Revive Therapeutics Ltd., a life sciences firm, specializes in the research and development of treatments for rare disorders and infectious diseases. The company’s pharmaceutical pipeline features a cannabinoid portfolio focused on rare inflammatory...

Revive Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

RVVTF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:RAMMTSE:RAMM47NeutralCAD 1.19M-0.07-194.41%―-66.40%31.38%
TSE:PCLOTSE:PCLO23UnderperformCAD 8.97M-2.4128.59%―0.90%57.73%

* Healthcare Sector Average

Performance Comparison

0%200%400%RVVTFTSE:PCLOTSE:RAMMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
RVVTF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
RVVTFRevive Therapeutics0.010.0020.00%
TSE:PCLOPharmacielo0.040.000.00%
TSE:RAMMRamm Pharma Corp0.01-0.05-83.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.